Thu, Apr 17, 2014, 10:27 AM EDT - U.S. Markets close in 5 hrs 33 mins


% | $
Quotes you view appear here for quick access.

Impax Laboratories Inc. (IPXLE) Message Board

  • michiganstockman michiganstockman Mar 8, 2002 1:50 PM Flag

    called IR

    they said that the drop was attributed to S/P's move to go over the counter with clariton...

    they will most likely be issuing a press release on monday...

    i was impressed that after i left a voice mail, i was called back within 10 minutes...but still, that doesn't help my pocketbook

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Someone pls help. Called the co and no one was there to reply. How much in terms of revenues does the generic version of Clarion acct for? Is this sell off warranted or overkill, depends on est revs. Thank you in advance. Long and nervous.

    • Add it up yourself from the PR below ... 350mil/8bil = rough estimate of hit to future sales... i.e., a 5% drop would be more appropriate here... not 30%

      HAYWARD, Calif.--(BW HealthWire)--Feb. 12, 2002--IMPAX Laboratories, Inc. IPXL today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Allegra-D(R) (Fexofenadine HCl/Pseudoephedrine HCl) Extended Release 60 mg/120mg Tablets.

      Aventis Pharmaceuticals Inc. markets Allegra-D(R) for the relief of symptoms associated with seasonal rhinitis in adults and children 12 years of age and older. U.S. sales of Allegra-D(R) Extended Release Tablets were over $350 million in 2001.

      IMPAX currently has fifteen ANDA filings pending at the FDA that address more than $8 billion in U.S. branded product sales. Nine of these filings were made under Paragraph IV of the Hatch-Waxman Amendments.


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.